Pay in 4 interest-free payments of $6.07 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
BPC-157 + TB-500 BLEND 2MG/2MG Research Grade The BPC-157 + TB-500 Research Blend co-delivers 2mg of BPC-157 (CAS 137525-51-0) and 2mg of TB-500 (CAS 77591-33-4) in a single co-lyophilised vial
Thanksss Hi I am going through the same thing it is awful I am so depressed
Researched applications In the published preclinical and clinical literature the effects of AOD-9604 are documented in the following areas: Obesity , Phase 2b failure (2007), but a complementary mechanism in combination protocols Lipolysis in animal models , robustly demonstrated (Heffernan 2001, Ng 2009) Inhibition of lipogenesis , demonstrated in hepatocytes and adipocytes Osteoarthritis and cartilage regeneration , emerging Phase 1/2 data (mLuna Pharmaceuticals 2018+) Tendinopathy , preclinical models Age-related sarcopenia (cachexia) , exploratory plans Lipodystrophy , preclinical data in animal models Hyperlipidemia , secondary endpoints in Phase 2 trials Science & studies 4.1 Key publications Heffernan M., Summers R.J., Thorburn A., et al
Adults need 2.4 micrograms (mcg) daily, with slightly higher amounts during pregnancy or chestfeeding
